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Abstract (Word count: 209) 
Background: Helicobacter pylori (H. pylori) is associated with an increased risk of gastric 
adenocarcinoma and gastric mucosa associated lymphoid tissue (MALT) lymphoma, and a 
seemingly decreased risk of oesophageal adenocarcinoma. We aimed to assess how 
eradication therapy for H. pylori influences the risk of developing these cancers. 
Methods: This was a systematic review and meta-analysis. We searched PubMed, Web of 
Science, Embase and the Cochrane Library and selected articles that examined the risk of 
gastric cancer, MALT lymphoma or oesophageal cancer following eradication therapy, 
compared to a non-eradicated control group.  
Results: Among 3629 articles that were considered, 9 met the inclusion criteria. Of these, 8 
cohort studies assessed gastric cancer, while 1 randomized trial assessed oesophageal cancer. 
Out of 12,899 successfully eradicated patients, 119 (0.9%) developed gastric cancer, 
compared to 208 (1.1%) out of 18,654 non-eradicated patients. The pooled relative risk of 
gastric cancer in all 8 studies was 0.46 (95% confidence interval 0.32-0.66, I2 32.3%) 
favouring eradication therapy. The 4 studies adjusting for time of follow-up and confounders 
showed a relative risk of 0.46 (95% confidence interval 0.29-0.72, I2 44.4%).  
Conclusion: This systematic review and meta-analysis indicates that eradication therapy for 
H. pylori prevents gastric cancer. There was insufficient literature for meta-analysis of MALT 
lymphoma or oesophageal cancer. 
 
Keywords: Stomach neoplasms, oesophageal neoplasms, Helicobacter pylori, eradication. 
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Introduction 
Helicobacter pylori (H. pylori) is a bacterium found in the stomachs of half of 
the adult human population and is typically acquired during childhood.[1] H. pylori is 
associated with chronic gastritis, peptic ulcer, and gastric cancer, particularly in the presence 
of its virulence factor CagA.[2] The incidence of gastric cancer is declining, possibly due to 
the decrease in H. pylori prevalence,[3] but is still the 5th most common cancer and the 3rd 
most common cause of cancer death globally.[4] The overall yearly incidence rates globally 
are 15.6-18.1 and 6.7-7.8 per 100,000 individuals in men and women, respectively.[5] There 
are considerable variations in incidence geographically, and half of all cases occur in Eastern 
Asia.[4] Gastric cancer is typically adenocarcinoma (95%), which is sub-classified into 
intestinal or diffuse type, both associated with H. pylori,[6-8] and mixed type. The intestinal 
type (54%)[9] develops from a gastric mucosa with chronic gastritis, atrophy, intestinal 
metaplasia, and dysplasia to invasive adenocarcinoma.[10] For the diffuse type (15%)[9] the 
carcinogenic pathway is less clear. The remaining adenocarcinomas (32%) are of the mixed 
type. Gastric mucosa associated lymphoid tissue (MALT) lymphomas are also associated with 
H. pylori.[11] Interestingly, H. pylori seemingly decreases the risk of oesophageal 
adenocarcinoma.[12] A possible explanation is that H. pylori-related atrophic gastritis reduces 
gastric acid secretion, which in turn counteracts gastro-oesophageal reflux, a main risk factor 
for this cancer.[12] The increasing incidence of oesophageal adenocarcinoma might be due to 
the decreasing prevalence of H. pylori.[13] CagA positive H. pylori strains might also be 
associated with an increased risk of oesophageal squamous cell carcinoma.[14] In theory, H. 
pylori eradication should reduce the risk of gastric adenocarcinoma, MALT lymphoma and 
oesophageal squamous cell carcinoma, and increase the risk of oesophageal adenocarcinoma. 
However, the available literature is limited. Two previous meta-analyses have indicated a 
decreased risk of gastric adenocarcinoma, while no meta-analysis has examined MALT 
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lymphoma or oesophageal cancer.[15,16] We aimed to examine the role of H. pylori 
eradication therapy in the development of gastric adenocarcinoma, MALT lymphoma and 
oesophageal cancer in a systematic review and meta-analysis. 
 
Methods 
This was a systematic review and meta-analysis analysing the risk of gastric 
adenocarcinoma, MALT lymphoma and oesophageal cancer after eradication therapy for H. 
pylori. The study was performed according to an a priori established study protocol.  
 
Exposure and outcome 
The study exposure was H. pylori eradication therapy. All established 
eradication regimens were considered eligible. H. pylori positive individuals who did not 
receive eradication, and individuals for whom eradication was unsuccessful, were considered 
unexposed (non-eradicated). The outcomes were gastric or oesophageal malignancy, where 
the following histological subtypes were considered for inclusion: adenocarcinoma, squamous 
cell carcinoma, or MALT lymphoma.[17,18]  
 
Search strategy and study selection 
We conducted a systematic search of the medical literature using PubMed, Web 
of Science, Embase and the Cochrane Library up until November 2015. There were no 
restrictions regarding article language or date of publication. Articles were considered eligible 
if the risk of cancer was evaluated in individuals receiving eradication therapy, compared to a 
control group that did not receive eradication or in which eradication was unsuccessful. Only 
studies describing a population representative of the general population or representative of 
individuals receiving H. pylori screening and treatment in clinical practice were considered 
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eligible. The following search terms were used : ‘Helicobacter pylori’, ‘campylobacter’, 
‘eradication’, ‘chemoprevention’, ‘oesophageal neoplasms’, ‘oesophageal’, ‘stomach 
neoplasms’, ‘gastric’, ‘cancer’, ‘carcinoma’, ‘tumour’, ‘adenocarcinoma’, ‘malignancy’ 
(taking into account both British and American spelling), and the names of different 
medications used for H. pylori eradication. A detailed search description can be found in the 
supplementary documents (Appendix). The results of the search were first evaluated based on 
article titles by one researcher (ED). The next step of the search was performed by two 
independent researchers (ED and NB), who evaluated the abstracts and full texts of the 
remaining articles. Any disagreement between the researchers was solved by consensus. 
Initial exclusion criteria were animal studies, studies without original data (including 
commentaries and editorials), meeting abstracts, case reports, and case-control studies. The 
latter were excluded to maintain comparability of measures of effect. Furthermore, we applied 
backwards and forward citation tracking (sources cited in included articles and identifying 
articles that cited the included articles) to all included articles, to identify other possible 
relevant studies. For studies that reported cancer development after eradication therapy for H. 
pylori, but did not report the number of cancer cases in the control group, we contacted the 
authors to provide these data to be able to include these articles. When we found multiple 
articles based on the same study population, we included only the most recent article (with the 
longest follow-up).  
 
Data extraction and quality assessment 
Data extraction on cancer development was performed independently by two 
researchers (ED and NB), who extracted both unadjusted data (i.e. absolute numbers) and 
adjusted data while taking into account the follow-up time (from Cox or Poisson models). The 
following data were extracted for each study: geographical location, method to detect H. 
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pylori, H. pylori eradication regimen, success of eradication, age (mean and range), sex ratio, 
follow-up time, and the histological type of the cancer.   
Two researchers (ED and NB) independently assessed the quality of the studies according to 
the Newcastle Ottawa scale.[19] The quality of each study was assessed by the following 
items: representativeness of the exposed cohort, selection of the non-exposed cohort, 
ascertainment of the exposure, demonstration that the outcome of interest was not present at 
the onset of the study, comparability of study cohorts on the basis of the design or analysis, 
assessment of outcome, length and adequacy of the follow-up of the cohorts. Studies with a 
score ≤3 were considered of low quality, 4 and 5 of moderate quality, while a score ≥6 
defined good quality.  
 
Data synthesis and statistical analysis 
For the pooled analyses we used a random effect model to take heterogeneity 
within and between studies into account. H. pylori eradication was compared to no eradication 
or unsuccessful eradication and expressed as unadjusted risk ratios (RR) with 95% confidence 
intervals (95% CI) for the development of cancer. A second analysis was used to pool the 
adjusted RR and 95% CI, taking into account follow-up time, in which the adjusted (full 
model) reported hazard or incidence ratios were used. To assess heterogeneity we used the I2 
statistic, where an I2 of >50% was used to define a substantial degree of heterogeneity. 
Subgroup analyses were performed for baseline gastric histology and type of control group to 
investigate possible explanations for any heterogeneity. A funnel plot and Egger’s test were 
conducted, where a large p-value (>0.05) indicated no evidence of small study effects or 
publication bias. The statistical analyses were performed using the statistical software Stata 
(Stata Corporation, version 12.1).  
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Results 
Study selection 
The systematic search identified 3629 unique articles (Figure 1). After screening 
of the titles and abstracts, the full texts of 38 articles remained for further evaluation of 
eligibility. None of these studies assessed the risk of MALT lymphoma and only one study 
assessed the risk of oesophageal cancer.[20] Four studies were excluded because of the 
design; 1 was a case-control study,[21] and 3 others were comments without original data.[22-
24] Three studies were excluded because they were reviews or gave notice of an ongoing 
study and thus contained no new data.[25-27] Other studies were excluded for various reasons 
as shown in Figure 1.[28-31] Nine studies were randomized controlled trials (RCTs) already 
described in the most recent meta-analysis,[20,32-39] and no new RCTs were identified after 
that meta-analysis.[15] After this evaluation of the literature, we restricted our study to cohort 
studies when examining gastric cancer. Seven other articles were excluded because no 
suitable control group was described,[40-44] or the risk of cancer was not reported in the 
control group, nor retrieved after contacting the authors.[45,46] Four other articles described 
the cancer risk based on the same population,[47-50] so only the most recent article with the 
longest follow-up was included.[50] After this review, eight observational studies assessing 
the risk of gastric cancer were selected for final analysis.[50-57] One study, a randomized 
clinical trial, assessing the risk of oesophageal cancer was included.[20]   
 
Study characteristics 
Patient characteristics for the eight studies examining gastric cancer are 
presented in Table 1. Seven of the studies were conducted in Japan and one in Finland. Five 
studies compared successful with unsuccessful eradication attempt,[50-54] and three studies 
compared eradicated individuals with untreated individuals with H. pylori.[55-57] The age 
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range was 17 to 83 years,[50] with mean ages between 50[50] and 63 years.[56] Most studies 
included more men than women (Table 1), particularly in one of the studies on factory 
workers (98% men).[55] Three studies described the baseline gastric histopathology of the 
patients, while the other five did not. In one study, all patients (100%) had gastric 
atrophy,[50] and in another study only 5-7% had atrophic gastritis.[52] One study included 
patients with intestinal metaplasia and a large (undefined) proportion of participants presented 
with atrophy at baseline.[57] None of the studies included patients with dysplasia or early 
gastric cancer at baseline. Table 2 describes the eradication therapies used. Success of 
eradication was measured in five out of eight studies, and the success rate varied between 
65%[54] and 87%.[55] Gastric cancer development and follow-up of patients is described in 
Table 3. The mean follow-up time ranged from 2.9 years[52] to 10.9 years.[51] The majority 
(up to 89%) of the cancers in both treatment and control groups were intestinal type gastric 
adenocarcinomas. In the treatment group in one study[50] and the control group of another 
study[54] there were similar proportions of diffuse and intestinal type adenocarcinomas.  
 
Quality assessment of included studies 
Of the eight studies, seven were considered of good quality[50-55,57] and one 
of moderate quality.[56] All studies included a control group from the same community as the 
exposed group and had a good ascertainment of the outcome. All but one study had a good 
assessment of the exposure, yet in one study it was not clear if eradication was successful in 
all patients because of incomplete data.[51] In two studies, the eradicated group was a 
selected group of individuals (i.e. factory workers).[50,55] One study could not demonstrate 
that gastric cancer was not present at start.[51] Two studies had a rather short follow-up time, 
with a mean around 3 years.[52,56] One study had a limited completeness of follow-up (56%) 
and there was no description of the individuals lost to follow-up,56 and 1 study had no 
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statement about follow-up of the cohort members.53 Four studies reported risk estimates 
adjusted for time for follow-up and confounding.50,52,54,56 The confounders adjusted for were 
not specified in one study,56 while the other three studies adjusted for age and sex. One study 
further adjusted for alcohol use, tobacco smoking, and gastric mucosal atrophy,50 another for 
the indication for H. pylori eradication,52 and the last one also adjusted for location of peptic 
ulcer, salt consumption, and tobacco smoking.54  
 
Helicobacter pylori eradication therapy and gastric cancer risk 
Among 12,899 patients who were successfully eradicated, 119 (0.9%) 
developed gastric cancer during follow-up, while such cancer was found in 208 out of 18,654 
(1.1%) in the non-eradicated group. The pooled analysis of all 8 included studies provided an 
RR of 0.46 (95% CI 0.32-0.66) in favour of eradication therapy (Figure 2). The heterogeneity 
was low (I2 32.3%) and there was no evidence of small study effects or publication bias 
(p=0.333). When the Finish study was excluded, because of the low incidence of gastric 
cancer in Finland compared to East-Asian countries, the seven Japanese studies provided a 
pooled RR of 0.40 (95% CI 0.29-0.54, I2 0.0%). Another sensitivity analysis excluding the 
study where a proportion of the participants had intestinal metaplasia at baseline yielded an 
RR of 0.48 (95% CI 0.34-0.66, I2 24.2%). The five studies comparing successful versus 
unsuccessful eradication showed an RR of 0.47 (95% CI 0.31-0.71, I2 40.9%), and the three 
studies comparing eradicated with non-eradicated individuals showed an RR of 0.39 (95% CI 
0.14-1.08, I2 49.9%) (Figure 2). The five studies not reporting baseline gastric histopathology 
(atrophy, intestinal metaplasia or dysplasia) showed an RR of 0.52 (95% CI 0.35-0.77, I2 
35.7%), and the three studies including patients with aberrant baseline histology (gastric 
atrophy or intestinal metaplasia) showed an RR of 0.28 (95% CI 0.11-0.72, I2 40.9%) (forest 
plot not shown). Four studies reported RRs adjusted for follow-up time and confounding, of 
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which three were analysed using Cox regression and one using Poisson regression, resulting 
in a pooled adjusted RR of 0.46 (95% CI 0.29-0.72, I2 44.4%), and 0.33 (95% CI 0.19-0.59) 
when including only the three studies using Cox regression (Figure 3).   
 
Helicobacter pylori eradication therapy and oesophageal cancer risk 
The only study assessing the risk of oesophageal cancer was performed in 
China, and compared eradication to placebo treatment.[20] The mean age was 42 years (range 
35 to 65) and the proportion of men to women was similar in both groups. The eradication 
rate was 84%. Two out of 817 (0.2%) individuals who received eradication therapy developed 
oesophageal cancer, compared to 1 out of 813 (0.1%) individuals who received placebo; all 
three cancers were squamous cell carcinomas.[20]  
 
Discussion 
This meta-analysis indicates that eradication therapy for H. pylori prevents 
gastric adenocarcinoma. The literature is insufficient to allow analysis of the risk of MALT 
lymphoma or oesophageal cancer following eradication in a meta-analysis. 
 
The main strength of this meta-analysis is that by including only cohort studies 
we were able to conduct an objective analysis on a large number of participants over a long 
follow-up period. The eight included studies are based on cohorts close to clinical practice 
without obvious selection issues. The fact that the studies presenting both unadjusted and 
adjusted results showed similar effect sizes indicates lack of strong confounding by the factors 
adjusted for. Also, this study was based on an a priori established study protocol and a 
thorough systematic search of the literature. Limitations of meta-analyses in general are that 
the validity is dependent on the quality of the included studies, heterogeneity between studies, 
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and on possible publication bias. The quality was considered good in seven out of eight 
studies and moderate in one, the statistical heterogeneity was low to moderate, and there was 
no evidence of small-study effects bias (publication bias). Moreover, the results were 
consistent in various sensitivity analyses. Analysis of studies comparing eradicated 
individuals with individuals not having undergone any attempt to treat the bacteria, and 
studies comparing eradicated individuals with unsuccessfully eradicated individuals showed 
similar results. The detection of H. pylori and consequent evaluation of success of eradication 
may have influenced the results, especially in the Finnish study where success of eradication 
was less clearly defined (a large proportion of patients did not have information regarding 
cure).[51] Outcome was measured with endoscopy in seven studies and extracted from a 
cancer registry in one study.[51] In three studies, patients presented with atrophy or intestinal 
metaplasia at baseline.[50,52,57] There were two studies performed on a selected group, 
namely male factory workers, who are likely to be healthier than the general population 
(“healthy worker effect”).[58] A limitation was that almost all studies were conducted in 
Japan, an area with a high incidence of gastric cancer, which questions whether the results are 
generalizable to non-Asian populations.  
 
The finding that H. pylori eradication therapy prevents gastric cancer is in line 
with the findings of two previous meta-analyses based on randomized clinical trials.[15,16] 
The relative risk of gastric cancer after eradication therapy compared to placebo or no 
treatment was 0.66 (95% CI 0.46-0.95) in the most recent meta-analysis, and thus our meta-
analysis yielded a stronger preventive effect. The earlier meta-analysis was performed on the 
same randomized clinical trials, but included data from one randomized clinical trial 
twice.[16,59] Compared to the most recent meta-analysis, which investigated the risk of 
gastric cancer after H. pylori eradication in healthy asymptomatic individuals in six individual 
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randomized clinical trials with follow-up ranging from maximum 5 to 14.7 years,[15] the 
present meta-analysis included studies with a longer follow-up (up to 20 years)[51] and 
almost four times more treated individuals, and more than five times more controls. Most of 
the randomized clinical trials included in the previous meta-analyses were conducted in 
China, leading to a limited generalizability of the results (similar to the present study). 
Furthermore, cohort studies better resemble clinical practice and reduce selection of 
participants compared to randomized clinical trials.  
 
There is a debate whether H. pylori eradication prevents gastric cancer. There 
are suggestions that once the histology has reached the level of intestinal metaplasia in the 
gastric adenocarcinoma development pathway, eradication therapy may no longer have cancer 
preventive effects.[60] However, it is likely that H. pylori eradication lowers the risk of 
gastric cancer compared to no treatment,[61] which is supported by the findings of the present 
meta-analysis and the two previous meta-analyses. H. pylori is more strongly associated with 
the risk of intestinal type of gastric adenocarcinoma than with the diffuse type.[62] In one 
study it was suggested that H. pylori eradication would prevent only the intestinal type, 
because the diffuse type developed only in individuals cured from H. pylori infection.[47] In 
the present study, the results indicate a similarly strong preventive role of eradication for both 
histological types of gastric adenocarcinoma. 
 
To conclude, this systematic review and meta-analysis of eight cohort studies 
and 31,553 patients indicates that eradication therapy for H. pylori prevents gastric cancer. 
Research examining H. pylori eradication in relation to the risk of gastric MALT lymphoma 
and oesophageal cancer is currently too limited to enable meta-analyses. 
 
 
13 
 
References 
 
1. Bjorkholm B, Falk P, Engstrand L, et al. Helicobacter pylori: resurrection of the 
cancer link. J Intern Med 2003;253(2):102-19. 
2. Schistosomes, liver flukes and Helicobacter pylori. IARC Working Group on 
the Evaluation of Carcinogenic Risks to Humans. Lyon, 7-14 June 1994. IARC Monogr Eval 
Carcinog Risks Hum 1994;61:1-241. 
3. Wang C, Weber A, Graham DY. Age, period, and cohort effects on gastric 
cancer mortality. Dig Dis Sci 2015;60(2):514-23. 
4. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality 
worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 
2015;136(5):E359-86. 
5. Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J 
Clin 2015;65(2):87-108. 
6. Cancer Research UK. http://www.cancerresearchuk.org/about-
cancer/type/stomach-cancer/about/types-of-stomach-cancer (accessed Aug 7, 2015). 
7. Lauren P. The two histological main types of gastric carcinoma: diffuse and so-
called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol 
Microbiol Scand 1965;64:31-49 
8. Parsonnet J, Friedman GD, Orentreich N, et al. Risk for gastric cancer in people 
with CagA positive or CagA negative Helicobacter pylori infection. Gut 1997;40(3):297-301. 
9. Polkowski W, van Sandick JW, Offerhaus GJ, et al. Prognostic value of Lauren 
classification and c-erbB-2 oncogene overexpression in adenocarcinoma of the esophagus and 
gastroesophageal junction. Ann Surg Oncol 1999;6(3):290-7. 
14 
 
10. Correa P. Human gastric carcinogenesis: a multistep and multifactorial process--
First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. 
Cancer Res 1992;52(24):6735-40. 
11. Farinha P, Gascoyne RD. Helicobacter pylori and MALT lymphoma. 
Gastroenterology 2005;128(6):1579-605. 
12. Xie FJ, Zhang YP, Zheng QQ, et al. Helicobacter pylori infection and 
esophageal cancer risk: an updated meta-analysis. World J Gastroenterol 2013;19(36):6098-
107. 
13. McColl KE, Going JJ. Aetiology and classification of adenocarcinoma of the 
gastro-oesophageal junction/cardia. Gut 2010;59(3):282-4. 
14. Ye WM, Held M, Lagergren J, et al. Helicobacter pylori infection and gastric 
atrophy: Risk of adenocarcinoma and squamous-cell carcinoma of the esophagus and 
adenocarcinoma of the gastric cardia. J Natl Cancer Inst 2004;96(5):388-396. 
15. Ford AC, Forman D, Hunt RH, et al. Helicobacter pylori eradication therapy to 
prevent gastric cancer in healthy asymptomatic infected individuals: systematic review and 
meta-analysis of randomised controlled trials. BMJ  2014;348. 
16. Fuccio L, Zagari RM, Eusebi LH, et al. Meta-analysis: Can Helicobacter pylori 
Eradication Treatment Reduce the Risk for Gastric Cancer? Ann Intern Med 2009;151(2):121-
W32. 
17. Parsonnet J, Hansen S, Rodriguez L, et al. Helicobacter pylori infection and 
gastric lymphoma. N Engl J Med 1994;330(18):1267-71. 
18. Sagaert X, Van Cutsem E, De Hertogh G, et al. Gastric MALT lymphoma: a 
model of chronic inflammation-induced tumor development. Nat Rev Gastroenterol Hepatol 
2010;7(6):336-46. 
15 
 
19. Wells GA SB OCD, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-
Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analysis. 
www.ohri.ca/programs/clinical_epidemiology/oxford.asp. 
20. Wong BCY, Lam SK, Wong WM, et al. Helicobacter pylori Eradication to 
Prevent Gastric Cancer in a High-Risk Region of China: A Randomized Controlled Trial. 
JAMA 2004;291(2):187-194. 
21. Kokkola A, Sipponen P, Arkkila P, et al. Does the eradication of Helicobacter 
pylori delay the diagnosis of gastric cancer? Scand J Gastroentero 2008;43(12):1456-1460. 
22. Kabir A. Role of age in association between gastric cancer and Helicobacter 
pylori eradication in cases with intestinal metaplasia and dysplasia. Gastric Cancer 2015; 
10.1007/s10120-015-0498-8. 
23. Sheu BS, Lin XZ. H. pylori eradication does not reduce gastric cancer incidence 
in a high-risk area of China. Evidence-Based Healthcare 2004;8(4):218-220. 
24. Wang Z, Yu Y, Yang WJ, et al. Does Helicobacter pylori eradication really 
reduce the risk of gastric cancer at the population level? Gut 2013;62(6):950-950. 
25. Kato M, Asaka M, Ono S, et al. Eradication of Helicobacter pylori for primary 
gastric cancer and secondary gastric cancer after endoscopic mucosal resection. J 
Gastroenterol 2007;42:16-20. 
26. Kim YJ, Chung WC. [Does Helicobacter pylori eradication therapy reduce the 
risk of developing gastric cancer in healthy asymtomatic individuals?]. Korean J 
Gastroenterol 2014;64(1):62-5. 
27. Lam SK. Eradication of Helicobacter pylori and gastric cancer: Experience in 
Fujian Province of China. Chinese Journal of Digestive Diseases 2005;6(3):116-118. 
28. Fall K, Ye W, Nyren O. Antibiotic treatment and risk of gastric cancer. Gut 
2006;55(6):793-6. 
16 
 
29. Lee YC, Chen THH, Chiu HM, et al. The benefit of mass eradication of 
Helicobacter pylori infection: a community-based study of gastric cancer prevention. Gut 
2013;62(5):676-682. 
30. Shichijo S, Hirata Y, Yoshida S, et al. Histological intestinal metaplasia and 
endoscopic atrophy are predictors of gastric cancer development after helicobacter pylori 
eradication. Gastroenterology 2015;148(4):S563-S564. 
31. Pan KF, Zhang L, Gerhard M, et al. A large randomised controlled intervention 
trial to prevent gastric cancer by eradication of Helicobacter pylori in Linqu County, China: 
baseline results and factors affecting the eradication. Gut 2015; 10.1136/gutjnl-2015-309197. 
32. Leung WK, Lin SR, Ching JY, et al. Factors predicting progression of gastric 
intestinal metaplasia: results of a randomised trial on Helicobacter pylori eradication. Gut 
2004;53(9):1244-9. 
33. Li WQ, Ma JL, Zhang L, et al. Effects of helicobacter pylori treatment on 
gastric cancer incidence and mortality in subgroups. J Natl Cancer Inst 2014;106(7). 
34. Ma JL, Zhang L, Brown LM, et al. Fifteen-year effects of helicobacter pylori, 
garlic, and vitamin treatments on gastric cancer incidence and mortality. J Natl Cancer Inst 
2012;104(6):488-492. 
35. Miehlke S, Kirsch C, Dragosics B, et al. Helicobacter pylori and gastric cancer: 
Current status of the Austrian-Czech-German gastric cancer prevention trial (PRISMA-
Study). World J Gastroentero 2001;7(2):243-247. 
36. Wong BCY, Zhang L, Ma JL, et al. Effects of selective COX-2 inhibitor and 
Helicobacter pylori eradication on precancerous gastric lesions. Gut 2012;61(6):812-818. 
37. You WC, Brown LM, Zhang L, et al. Randomized double-blind factorial trial of 
three treatments to reduce the prevalence of precancerous gastric lesions. J Natl Cancer Inst 
2006;98(14):974-83. 
17 
 
38. Zhou LY, Lin SR, Ding SG, et al. The changing trends of the incidence of 
gastric cancer after Helicobacter pylori eradication in Shandong area. Chinese Journal of 
Digestive Diseases 2005;6(3):114-115. 
39. Zhou LY, Lin SR, Ding SG, et al. Relationship of Helicobacter pylori 
eradication with gastric cancer and gastric mucosal histological changes: a 10-year follow-up 
study. Chinese Med J 2014;127(8):1454-1458. 
40. Sakitani K, Hirata Y, Suzuki N, et al. Gastric cancer diagnosed after 
Helicobacter pylori eradication in diabetes mellitus patients. BMC Gastroenterol 
2015;15(1):143. 
41. Duggan AE, Elliott CA, Miller P, et al. Clinical trial: a randomized trial of early 
endoscopy, Helicobacter pylori testing and empirical therapy for the management of 
dyspepsia in primary care. Aliment Pharmacol Ther 2009;29(1):55-68. 
42. Tashiro J, Miwa J, Tomita T, et al. Gastric cancer detected after Helicobacter 
pylori eradication. Digest Endosc 2007;19(4):167-173. 
43. Kamada T, Hata J, Sugiu K, et al. Clinical features of gastric cancer discovered 
after successful eradication of Helicobacter pylori: results from a 9-year prospective follow-
up study in Japan. Aliment Pharmacol Ther 2005;21(9):1121-1126. 
44. Wu CY, Kuo KN, Wu MS, et al. Early Helicobacter pylori Eradication 
Decreases Risk of Gastric Cancer in Patients With Peptic Ulcer Disease. Gastroenterology 
2009;137(5):1641-1648. 
45. Seto K, Seto Y. Prevalence of Helicobacter pylori infection, eradication therapy, 
and effectiveness of eradication in cancer suppression or prevention. Japan Medical 
Association Journal 2005;48(10):480-488. 
18 
 
46. Kodama M, Murakami K, Okimoto T, et al. Ten-year prospective follow-up of 
histological changes at five points on the gastric mucosa as recommended by the updated 
Sydney system after Helicobacter pylori eradication. J Gastroenterol 2012;47(4):394-403. 
47. Take S, Mizuno M, Ishiki K, et al. The effect of eradicating helicobacter pylori 
on the development of gastric cancer in patients with peptic ulcer disease. Am J Gastroenterol 
2005;100(5):1037-42. 
48. Take S, Mizuno M, Ishiki K, et al. Baseline gastric mucosal atrophy is a risk 
factor associated with the development of gastric cancer after Helicobacter pylori eradication 
therapy in patients with peptic ulcer diseases. J Gastroenterol 2007;42:21-27. 
49. Take S, Mizuno M, Ishiki K, et al. The long-term risk of gastric cancer after the 
successful eradication of Helicobacter pylori. J Gastroenterol 2011;46(3):318-324. 
50. Take S, Mizuno M, Ishiki K, et al. Seventeen-year effects of eradicating 
Helicobacter pylori on the prevention of gastric cancer in patients with peptic ulcer; a 
prospective cohort study. J Gastroenterol 2014; 10.1007/s00535-014-1004-5. 
51. Kosunen TU, Pukkala E, Sarna S, et al. Gastric cancers in Finnish patients after 
cure of Helicobacter pylori infection: A cohort study. Int J Cancer 2011;128(2):433-9. 
52. Takenaka R, Okada H, Kato J, et al. Helicobacter pylori eradication reduced the 
incidence of gastric cancer, especially of the intestinal type. Aliment Pharmacol Ther 
2007;25(7):805-812. 
53. Kato M, Asaka M, Nakamura T, et al. Helicobacter pylori eradication prevents 
the development of gastric cancer - results of a long-term retrospective study in Japan. 
Aliment Pharmacol Ther 2006;24:203-206. 
54. Mabe K, Takahashi M, Oizumi H, et al. Does Helicobacter pylori eradication 
therapy for peptic ulcer prevent gastric cancer? World J Gastroentero 2009;15(34):4290-
4297. 
19 
 
55. Yanaoka K, Oka M, Ohata H, et al. Eradication of Helicobacter pylori prevents 
cancer development in subjects with mild gastric atrophy identified by serum pepsinogen 
levels. Int J Cancer 2009;125(11):2697-2703. 
56. Ogura K, Hirata Y, Yanai A, et al. The effect of Helicobacter pylori eradication 
on reducing the incidence of gastric cancer. J Clin Gastroenterol 2008;42(3):279-283. 
57. Uemura N, Okamoto S, Yamamoto S, et al. Helicobacter pylori infection and 
the development of gastric cancer. N Engl J Med 2001;345(11):784-9. 
58. Baillargeon J. Characteristics of the healthy worker effect. Occup Med 
2001;16(2):359-66. 
59. Ford AC, Moayyedi P. Redundant data in the meta-analysis on Helicobacter 
pylori eradication. Ann Intern Med 2009;151(7):513; author reply 513-4. 
60. Chen HN, Wang Z, Li X, et al. Helicobacter pylori eradication cannot reduce the 
risk of gastric cancer in patients with intestinal metaplasia and dysplasia: evidence from a 
meta-analysis. Gastric Cancer 2015. 
61. Leontiadis GI, Ford AC. Helicobacter pylori eradication: gastric cancer 
prevention. BMJ Clin Evid 2015;2015. 
62. Parsonnet J, Vandersteen D, Goates J, et al. Helicobacter pylori infection in 
intestinal- and diffuse-type gastric adenocarcinomas. J Natl Cancer Inst 1991;83(9):640-3. 
 
 
20 
 
Table 1: Patient characteristics of studies included in a meta-analysis of Helicobacter pylori eradication and risk of gastric cancer. 
Study Males receiving 
eradication (%) 
Male control 
subjects (%) 
Age range 
among all 
included 
individuals 
(years) 
Mean age 
for those 
receiving 
eradication 
(years) 
Mean age 
among 
control 
subjects 
(years) 
Baseline histology of the gastric mucosa 
Uemura, 2001 57 NA 20-76 52 NA 53% moderate atrophy, 17% severe atrophy 
      37% intestinal metaplasia 
Kato, 2006 66 57 NA 55 53 Not reported 
Takenaka, 2007 71 NA NA 54 NA 5-7% atrophic gastritis 
Ogura, 2008 57 55 NA 62 63 Not reported 
Mabe, 2009 71 71 NA 52 58 Not reported 
Yanaoka, 2009 98 NA 40-60 NA NA Not reported 
Kosunen, 2011 44 44 NA 56 55 Not reported 
Take, 2014 89 
 
NA 
 
17-83 
 
50 
 
NA 
 
100% atrophy (mild to severe) 
NA: not available  
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Table 2:  Helicobacter pylori eradication strategy in studies included in a meta-analysis of eradication and risk of gastric cancer. 
 
Study Eradication regimen Method to detect H. pylori Successful 
eradication (%) 
Control group 
Uemura, 2001 Not available Rapid urease test, histology, 
serology 
not reported no eradication 
Kato, 2006 PPI triple therapy (lansoprazole 60mg, amoxicillin 1500mg and clarithromycin 400mg) Urea breath test or biopsy-based 
methods 
not reported unsuccessful eradication 
 2-week combination therapy with PPI and antibiotics    
Takenaka, 2007 Triple or dual therapy: amoxicillin 750mg, lansoprazole 30mg or omeprazole 20mg and 
(clarithromycin 200/400mg for triple therapy) 
Urea breath test, rapid urease test, 
histology, culture, serology 
85% unsuccessful eradication 
Ogura, 2008 7 days: lansoprazole 30mg, amoxicillin 750 or 1000mg and clarithromycin 400mg or metronidazole 
250mg, twice daily 
Urea breath test, rapid urease test, 
histology, culture, serology 
74% no eradication 
Mabe, 2009 7 days: 30mg lansoprazole or 20mg omeprazole; 750mg amoxicillin and 200 or 400mg 
clarithromycin, twice daily 
Rapid urease test 65% (ITT), 79% 
(PP) 
unsuccessful eradication 
Yanaoka, 2009 2 weeks: omeprazole 20 mg and amoxicillin 750 or 500mg, twice daily Serology 87% no eradication 
 1 week: omeprazole 20 mg; amoxicillin 750mg and clarithromycin 200mg, twice daily    
Kosunen, 2011 Not available Serology not reported unsuccessful eradication 
Take, 2014 2 weeks: amoxicillin 750mg and omeprazole 20mg or lansoprazole 30mg Rapid urease test, culture   85% unsuccessful eradication 
 1 week: amoxicillin 750mg; clarithromycin 200mg or 400mg and omeprazole 20mg or lansoprazole 
30mg or rabeprazole 10mg 
   
 
 
 
1 week: metronidazole 500mg; amoxicillin 750mg or clarithromycin 200mg and omeprazole 20mg 
or lansoprazole 30mg or rabeprazole 10mg 
 
 
  
  
 
 
 
 
 
 
 
 
PPI: proton pump inhibitor 
ITT: intention to treat, PP: per protocol 
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Table 3: Gastric cancer development following Helicobacter pylori eradication in a meta-analysis. 
Study Country Participants, 
treatment 
group, N 
Included 
in analysis, 
treatment^, 
N 
Cases of 
gastric cancer, 
treatment, N 
(%) 
Type of 
adenocarcinoma 
(intestinal/diffuse), 
treatment, N 
Participants, 
control group 
(N) 
Included 
in 
analysis, 
control 
(N) 
Cases of 
gastric 
cancer, 
control 
(%) 
Type of 
adenocarcinoma 
(intestinal/diffuse), 
control, N 
Mean 
follow-up in 
years 
(range), 
treatment 
Mean 
follow-up in 
years 
(range), 
control 
Uemura, 
2001 
Japan 253 253 0 (0) 0 993 993 36 (3.6) 23/13 4.8 8.5 
Kato, 2006 Japan 1788 1788 23 (1.3) 19/4 1233 1233 44 (3.6) 32/12 5.9 7.7 
Takenaka, 
2007 
Japan 2192 1519 6 (0.4) 4/2 373 288 5 (1.7) 4/1 3.25 (max. 
9.8) 
2.9 
Ogura, 
2008 
Japan 853 404 6 (1.5) NA 623 304 13 (4.3) NA 3.2 3.1 
Mabe, 2009 Japan 3781 3781 47 (1.2) 35/10* 352 352 9 (2.6) 5/4 5.6 (max. 
8.0) 
5.2 (max. 
8.4) 
Yanaoka, 
2009 
Japan 852 474 5 (1.1) 4/1 4924 3664 55 (1.5) 36/19 max. 10  max. 10  
Kosunen, 
2011 
Finland 3650 3650 11 (0.3) NA 11628 11628 37 (0.3) NA 10.4 (max. 
20) 
9.3 (max. 
20) 
Take, 2014 Japan 1135 1030 21 (2.0) 11/10 207 192 9 (4.7) 8/1 9.9 (max 
17.4) 
9.9 (max. 
17.4) 
NA: not available 
*2 cancers of unknown type 
^Number of patients included in the analysis after excluding those lost to follow-up.  
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Figure 1: Flow diagram of study selection adapted from PRISMA (Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses) for a meta-analysis assessing gastric cancer risk after 
Helicobacter pylori eradication.  
Articles identified through database 
searches (PubMed, Web of Science, 
Embase) 
(n=4729) 
Additional articles identified 
through other sources 
(n=1) 
Articles after duplicates removed 
(n=3629) 
Articles screened 
(n=3629) 
Articles excluded 
(n=3591) 
Full-text articles assessed 
for eligibility 
(n=38) 
Full-text articles excluded, 
with reasons 
- Randomised 
clinical trials 
(n=9) 
- Case-control study 
(n=1) 
- Comment (n=3) 
- Exposure of 
antibiotic use 
(n=1) 
- Unclear study 
(n=1) 
- No new 
data/review (n=3) 
- No outcomes yet 
(n=1) 
- Conference 
abstract (n=1) 
- No suitable 
control group 
(n=7) 
- Data on same 
population (n=3) 
Articles included in 
qualitative synthesis 
(n=8) 
Articles included in 
quantitative synthesis 
(meta-analysis) 
(n=8) 
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Figure 2: Forest plot of studies comparing eradication therapy to no treatment and studies comparing successful to 
unsuccessful treatment. CI, confidence interval; RR, relative risk
.
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Figure 3: Forest plot of studies comparing eradicated and not-eradicated groups which reported adjusted values, grouped by 
Cox or Poisson model. CI, confidence interval; RR, relative risk 
.
.
Overall  (I-squared = 44.4%, p = 0.145)
Poisson
Subtotal  (I-squared = .%, p = .)
Mabe
Takenaka
Subtotal  (I-squared = 0.0%, p = 0.596)
Take
Ogura
Author
Cox
2009
2007
2014
2008
Year
0.46 (0.29, 0.72)
0.61 (0.59, 0.63)
0.61 (0.59, 0.63)
0.20 (0.06, 0.66)
0.33 (0.19, 0.59)
0.42 (0.19, 0.92)
0.34 (0.11, 0.98)
RR (95% CI)
.
100.00
100.00
22.23
100.00
50.66
27.11
Weight
%
  1.1 .25.5 2 4
26 
 
Appendix: Detailed search strategy of systematic literature search 
Source Used search terms Settings Articles 
identified 
Most recent search 
PubMed 
(oesophageal) 
(("Helicobacter pylori"[Mesh] OR Helicobacter[tiab] OR pylori[tiab] OR campylobacter[tiab]) AND (eradication[tiab] 
OR chemoprevention[tiab] OR "proton pump inhibitor" OR PPI OR esomeprazole OR nexium OR omeprazole OR 
prilosec OR losec OR pantoprazole OR lansoprazole OR rabeprazole OR "histamine H2 antagonists" OR cimetidine OR 
ranitidine OR famotidine OR nizatidine OR "H2 receptor antagonist" OR H2RA OR "histamine2 receptor antagonist" OR 
amoxicillin OR bismuth OR clarithromycin OR "macrolides"[Mesh] OR "metronidazole"[Mesh] OR 
"nitroimidazoles"[Mesh])) AND ("Esophageal Neoplasms"[Mesh] OR (esophag*[tiab] OR oesophag*[tiab]) AND 
(cancer[tiab] OR carcinoma[tiab] OR neoplas*[tiab] OR tumor[tiab] OR tumour[tiab] OR malignan*[tiab] OR lesion[tiab] 
OR dysplasia[tiab] OR adenocarcinoma[tiab] OR "squamous cell carcinoma"[tiab])) 
 258 November 10th, 
2015 
Web of 
Science 
(oesophageal) 
(‘Helicobacter pylori’ OR Helicobacter OR pylori OR campylobacter) AND (eradication OR chemoprevention OR 
‘proton pump inhibitor’ OR PPI OR esomeprazole OR nexium OR omeprazole OR prilosec OR losec OR pantoprazole 
OR lansoprazole OR rabeprazole OR ‘histamine H2 antagonists’ OR cimetidine OR ranitidine OR famotidine OR 
nizatidine OR ‘H2 receptor antagonist’ OR H2RA OR ‘histamine2 receptor antagonist’ OR amoxicillin OR bismuth OR 
clarithromycin OR macrolides OR metronidazole OR nitroimidazoles) AND (‘Esophageal Neoplasms’ OR (esophag* OR 
oesophag*)) AND (cancer OR carcinoma OR neoplas* OR tumor OR tumour OR malignan* OR lesion OR dysplasia OR 
adenocarcinoma OR ‘squamous cell carcinoma’) 
In "topic" 617 November 10th, 
2015 
Embase 
(oesophageal) 
helicobacter pylori'/exp OR 'helicobacter pylori' OR helicobacter:ab,ti OR pylori:ab,ti OR campylobacter:ab,ti AND 
(eradication:ab,ti OR chemoprevention:ab,ti OR 'proton pump inhibitor'/exp OR 'proton pump inhibitor' OR ppi OR 
'esomeprazole'/exp OR esomeprazole OR 'nexium'/exp OR nexium OR 'omeprazole'/exp OR omeprazole OR 'prilosec'/exp 
OR prilosec OR 'losec'/exp OR losec OR 'pantoprazole'/exp OR pantoprazole OR 'lansoprazole'/exp OR lansoprazole OR 
'rabeprazole'/exp OR rabeprazole OR 'histamine h2 antagonists'/exp OR 'histamine h2 antagonists' OR 'cimetidine'/exp OR 
cimetidine OR 'ranitidine'/exp OR ranitidine OR 'famotidine'/exp OR famotidine OR 'nizatidine'/exp OR nizatidine OR 'h2 
receptor antagonist'/exp OR 'h2 receptor antagonist' OR h2ra OR 'histamine2 receptor antagonist' OR 'amoxicillin'/exp OR 
amoxicillin OR 'bismuth'/exp OR bismuth OR 'clarithromycin'/exp OR clarithromycin OR 'macrolides'/exp OR 
'macrolides' OR 'metronidazole'/exp OR 'metronidazole' OR 'nitroimidazoles'/exp OR 'nitroimidazoles') AND ('esophageal 
neoplasms'/exp OR 'esophageal neoplasms' OR esophag*:ab,ti OR oesophag*:ab,ti) AND (cancer:ab,ti OR 
carcinoma:ab,ti OR neoplas*:ab,ti OR tumor:ab,ti OR tumour:ab,ti OR malignan*:ab,ti OR lesion:ab,ti OR dysplasia:ab,ti 
OR adenocarcinoma:ab,ti OR 'squamous cell carcinoma':ab,ti)  
  557 November 10th, 
2015 
PubMed 
(gastric) 
(("Helicobacter pylori"[Mesh] OR Helicobacter[tiab] OR pylori[tiab] OR campylobacter[tiab]) AND (eradication[tiab] 
OR chemoprevention[tiab] OR "proton pump inhibitor" OR PPI OR esomeprazole OR nexium OR omeprazole OR 
prilosec OR losec OR pantoprazole OR lansoprazole OR rabeprazole OR "histamine H2 antagonists" OR cimetidine OR 
ranitidine OR famotidine OR nizatidine OR "H2 receptor antagonist" OR H2RA OR "histamine2 receptor antagonist" OR 
amoxicillin OR bismuth OR clarithromycin OR "macrolides"[Mesh] OR "metronidazole"[Mesh] OR 
"nitroimidazoles"[Mesh])) AND ("Stomach Neoplasms"[Mesh] OR (stomach[tiab] OR gastric[tiab]) AND (cancer[tiab] 
OR carcinoma[tiab] OR neoplas*[tiab] OR tumor[tiab] OR tumour[tiab] OR malignan*[tiab] OR lesion[tiab] OR 
dysplasia[tiab] OR adenocarcinoma[tiab] OR "mucosa associated lymphoid tissue"[tiab] OR MALT[tiab] OR 
lymphoma[tiab])) 
 2337 November 10th, 
2015 
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Web of 
Science 
(gastric) 
((‘Helicobacter pylori’ OR Helicobacter OR pylori OR campylobacter) AND (eradication OR chemoprevention OR 
‘proton pump inhibitor’ OR PPI OR esomeprazole OR nexium OR omeprazole OR prilosec OR losec OR pantoprazole 
OR lansoprazole OR rabeprazole OR ‘histamine H2 antagonists’ OR cimetidine OR ranitidine OR famotidine OR 
nizatidine OR ‘H2 receptor antagonist’ OR H2RA OR ‘histamine2 receptor antagonist’ OR amoxicillin OR bismuth OR 
clarithromycin OR macrolides OR metronidazole OR nitroimidazoles) AND (‘Stomach Neoplasms’ OR (gastric OR 
stomach)) AND (cancer OR carcinoma OR neoplas* OR tumor OR tumour OR malignan* OR lesion OR dysplasia OR 
adenocarcinoma OR ‘mucosa associated lymphoid tissue’ OR MALT OR lymphoma))  
In "title" 456 November 10th, 
2015 
Embase 
(gastric) 
‘helicobacter pylori'/exp OR 'helicobacter pylori' OR helicobacter:ti OR pylori:ti OR campylobacter:ti AND (eradication:ti 
OR chemoprevention:ti OR 'proton pump inhibitor'/exp OR 'proton pump inhibitor' OR ppi OR 'esomeprazole' OR 
'esomeprazole'/exp OR esomeprazole OR 'nexium' OR 'nexium'/exp OR nexium OR 'omeprazole' OR 'omeprazole'/exp 
OR omeprazole OR 'prilosec' OR 'prilosec'/exp OR prilosec OR 'losec' OR 'losec'/exp OR losec OR 'pantoprazole' OR 
'pantoprazole'/exp OR pantoprazole OR 'lansoprazole' OR 'lansoprazole'/exp OR lansoprazole OR 'rabeprazole' OR 
'rabeprazole'/exp OR rabeprazole OR 'histamine h2 antagonists'/exp OR 'histamine h2 antagonists' OR 'cimetidine' OR 
'cimetidine'/exp OR cimetidine OR 'ranitidine' OR 'ranitidine'/exp OR ranitidine OR 'famotidine' OR 'famotidine'/exp OR 
famotidine OR 'nizatidine' OR 'nizatidine'/exp OR nizatidine OR 'h2 receptor antagonist'/exp OR 'h2 receptor antagonist' 
OR h2ra OR 'histamine2 receptor antagonist' OR 'amoxicillin' OR 'amoxicillin'/exp OR amoxicillin OR 'bismuth' OR 
'bismuth'/exp OR bismuth OR 'clarithromycin' OR 'clarithromycin'/exp OR clarithromycin OR 'macrolides'/exp OR 
'macrolides' OR 'metronidazole'/exp OR 'metronidazole' OR 'nitroimidazoles'/exp OR 'nitroimidazoles') AND ('stomach 
neoplasms'/exp OR 'stomach neoplasms' OR gastric:ti OR stomach:ti) AND (cancer:ti OR carcinoma:ti OR neoplas*:ti OR 
tumor:ti OR tumour:ti OR malignan*:ti OR lesion:ti OR dysplasia:ti OR adenocarcinoma:ti OR 'mucosa associated 
lymphoid tissue':ti OR malt:ti OR lymphoma:ti)  
 803 November 10th, 
2015 
         
Additional 
sources 
Used search terms Settings Articles 
identified 
Most recent search 
Backward- 
and forwards 
citation 
tracking 
Screening reference lists of all selected articles + citation index (Web of Science) - 0  
Cochrane Screening PubMed for potentially eligible articles from same authors as selected articles - 0 November 10th, 
2015 
 
 
 
 
 
 
 
